

Fig 5. Mechanism underlying ventricular fibrillation (VF) in a Brugada model using a wedge preparation combined with high-resolution (256×256) optical mapping techniques. (A) Representative snapshots from a phase movie during VF originating from the epicardial (Epi) phase 2 reentry (P2R). (B) Optical action potentials at each site (a–f), together with a transmural ECG. (C, D) Repolarization and depolarization maps on the Epi surface in the condition of Brugada-ECG just before VF. (E) Epi action potential duration at 50% repolarization (APD₅₀) histogram during the first P2R-wave. The area of maximum gradient of repolarization in Epi (arrow in A and C) develops the P2R. The first P2R-wave is broken up into multiple wavelets (A, 220 ms), resulting in degeneration of ventricular tachycardia into VF. The Epi depolarization map paced from the endocardium shows a remarkable conduction delay in the episode of VF (D). The phase singularity points during the first P2R-wave (open circle in D) almost coincide with the Epi sites of delayed conduction. There is a large variety of APD in Epi during the first P2R-wave (E). Thus, P2R-extrasystoles degenerate into VF with further depolarization and repolarization disturbances. Open circles mark phase singularity points (Modified from *J Am Coll Cardiol* 2006; 47: 2074–2085 with permission).




Fig 6. Correlation between testosterone level and body mass index (BMI) in Brugada syndrome males and age-matched control males. Testosterone level inversely correlated with BMI in both groups (*J Cardiovasc Electrophysiol* 2007 (in press), with permission).

tral European general population⁴⁰ We recently identified a haplotype variant consisting of 6 individual DNA polymorphisms in near-complete linkage disequilibrium within the proximal promoter region of *SCN5A* in Asians only (an allele frequency of 22%), not in Caucasian or African-

Americans (Fig 7)⁴¹ Luciferase reporter activity of this variant haplotype, designated Haplotype B, in cardiomyocytes is reduced 62% compared with the wild-type, designated Haplotype A. To test the hypothesis that this *SCN5A* promoter polymorphism may modulate variability in cardiac




Fig 7. Haplotypes identified within the proximal promoter region of *SCN5A*, a cardiac sodium-channel gene. The 6 polymorphisms are in near-complete linkage disequilibrium. Haplotype A is designated as containing all common alleles, and Haplotype B as containing all minor alleles. The discordant haplotype is designated Haplotype C. *Frequency in the Japanese (control) population (Modified from *Circulation* 2006; 113: 338–344 with permission).




Fig 8. *SCN5A* promoter haplotype pair effects on QRS duration in lead V₆ and PR duration in lead II in patients with Brugada syndrome and in control subjects. In the Brugada patients without *SCN5A* mutations and in the control subjects, both QRS and PR duration show a gene–dose effect, being longest in Haplotype B homozygotes (BB), intermediate in Haplotype A/Haplotype B heterozygotes (AB) and shortest in Haplotype A homozygotes (AA). The Brugada patients with *SCN5A* mutations show the longer duration of both QRS and PR than do those without *SCN5A* mutations. Patient numbers are indicated between parentheses. Data mean±SD (Modified from *Circulation* 2006; 113: 338–344 with permission).

conduction, the relationship between the *SCN5A* promoter haplotype and indices of conduction velocity (ie. PR and QRS durations) was analyzed in a cohort of 71 Japanese BS subjects without *SCN5A* mutations and in 102 Japanese controls. In both groups, PR and QRS durations were significantly longer in Haplotype B individuals, with a gene–dose effect (Fig 8). Moreover, increases in both the PR and

QRS duration with sodium channel blockers, which are known to be arrhythmogenic in BS, were genotype-dependent and a gene–dose effect was also observed. These data demonstrate that the Haplotype B within the *SCN5A* promoter region alone does not give rise to BS, but that it likely contributes to a higher incidence of BS in Asian population in combination with other yet unknown (genetic) factors.

Acknowledgments

Dr W Shimizu was supported by the Uehara Memorial Foundation, the Hoansha Research Foundation, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science and Technology Leading Project for Biosimulation, and Health Sciences Research Grants (H18-Research on Human Genome-002) from the Ministry of Health, Labour and Welfare, Japan.

References

- Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome: A multicenter report. *J Am Coll Cardiol* 1992; **20**: 1391–1396.
- Alings M, Wilde A. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. *Circulation* 1999; **99**: 666–673.
- Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, et al. Brugada syndrome: A decade of progress. *Circ Res* 2002; **91**: 1114–1118.
- Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: Insights for risk stratification and management. *Circulation* 2002; **105**: 1342–1347.
- Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: Consensus report. *Circulation* 2002; **106**: 2514–2519.
- Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003; **108**: 3092–3096.
- Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada Syndrome: Report of the Second Consensus Conference: Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005; **111**: 659–670.
- Shimizu W, Aiba T, Kamakura S. Mechanisms of disease: Current understanding and future challenges in Brugada syndrome. *Nat Clin Pract Cardiovasc Med* 2005; **2**: 408–414.
- Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, et al. Body surface distribution and response to drugs of ST segment elevation in the Brugada syndrome: Clinical implication of 87-leads body surface potential mapping and its application to 12-leads electrocardiograms. *J Cardiovasc Electrophysiol* 2000; **11**: 396–404.
- Miyamoto K, Yokokawa M, Tanaka K, Nagai T, Okamura H, Noda T, et al. Diagnostic and prognostic value of type 1 Brugada electrocardiogram at higher (third or second) V1 to V2 recording in men with Brugada syndrome. *Am J Cardiol* 2007; **99**: 53–57.
- Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. *Circulation* 1997; **96**: 2595–2600.
- Atarashi H, Ogawa S, Harumi K, Sugimoto T, Inoue H, Murayama M, et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome: Idiopathic Ventricular Fibrillation Investigators. *J Am Coll Cardiol* 2001; **37**: 1916–1920.
- Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, et al. Electrophysiologic characteristics and implication of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. *J Am Coll Cardiol* 2002; **39**: 1799–1805.
- Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. *Circulation* 2005; **111**: 257–263.
- Shimizu W. Gender difference and drug challenge in Brugada syndrome (Editorial Comment). *J Cardiovasc Electrophysiol* 2004; **15**: 70–71.
- Shimizu W. The long QT syndrome: Therapeutic implications of a genetic diagnosis. *Cardiovasc Res* 2005; **67**: 347–356.
- Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. *Nature* 1998; **392**: 293–296.
- Weiss R, Barmada MM, Nguyen T, Seibel JS, Cavlovich D, Kornblit CA, et al. Clinical and molecular heterogeneity in the Brugada syndrome: A novel gene locus on chromosome 3. *Circulation* 2002; **105**: 707–713.
- Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. *Circulation* 2007; **115**: 442–449.
- Tan HL, Bezzina CR, Smits JP, Verkerk AO, Wilde AA. Genetic control of sodium channel function. *Cardiovasc Res* 2003; **57**: 961–973.
- Baroudi G, Acharfi S, Larouche C, Chahine M. Expression and intracellular localization of an SCN5A double mutant R1232W/T1620M implicated in Brugada syndrome. *Circ Res* 2002; **90**: E11–E16.
- Ye B, Valdivia CR, Ackerman MJ, Makielski JC. A common human SCN5A polymorphism modifies expression of an arrhythmia causing mutation. *Physiol Genomics* 2003; **12**: 187–193.
- Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. *Circ Res* 1988; **62**: 116–126.
- Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 Reentry? *Circulation* 1993; **87**: 562–5729.
- Yan GX, Antzelevitch C. Cellular basis for the electrocardiographic J wave. *Circulation* 1996; **93**: 372–379.
- Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. *Circulation* 1999; **100**: 1660–1666.
- Aiba T, Shimizu W, Hidaka I, Uemura K, Noda T, Zheng C, et al. Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: High resolution optical mapping study. *J Am Coll Cardiol* 2006; **47**: 2074–2085.
- Frustaci A, Priori SG, Pieroni M, Chimenti C, Napolitano C, Rivolta I, et al. Cardiac histological substrate in patients with clinical phenotype of Brugada syndrome. *Circulation* 2005; **112**: 3680–3687.
- Yokokawa M, Kitamura S, Okamura H, Noda T, Suyama K, Kurita T, et al. Long-term follow-up of electrocardiographic features in patients with Brugada syndrome: Comparison between SCN5A mutation carriers and non-mutation carriers (abstract). *Circulation* 2006; **114**: II-471.
- Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. *Circulation* 2002; **106**: 2004–2011.
- Shuba YM, Degtiar VE, Osipenko VN, Naidenov VG, Woosley RL. Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. *Biochem Pharmacol* 2001; **62**: 41–49.
- Liu XK, Katchman A, Whitfield BH, Wan G, Janowski EM, Woosley RL, et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchietomized male rabbits. *Cardiovasc Res* 2003; **57**: 28–36.
- Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Non-transcriptional regulation of cardiac repolarization currents by testosterone. *Circulation* 2005; **112**: 1701–1710.
- Matsuo K, Akahoshi M, Seto S, Yano K. Disappearance of the Brugada-type electrocardiogram after surgical castration: A role for testosterone and an explanation for the male preponderance. *Pacing Clin Electrophysiol* 2003; **26**: 1551–1553.
- Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab* 1977; **45**: 1211–1219.
- Matsuo K, Akahoshi M, Nakashima E, Seto S, Yano K. Clinical characteristics of subjects with the Brugada-type electrocardiogram: A case control study. *J Cardiovasc Electrophysiol* 2004; **15**: 653–657.
- Shimizu W, Matsuo K, Kokubo Y, Satomi K, Kurita T, Noda T, et al. Sex hormone and gender difference--role of testosterone on male predominance in Brugada syndrome. *J Cardiovasc Electrophysiol* 2007; **18**: 415–421.
- Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. *Hum Mol Genet* 2002; **11**: 337–345.
- Splawski I, Timothy KW, Tatemaya M, Clancy CE, Malhotra A, Beggs AH, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. *Science* 2002; **297**: 1333–1336.
- Pfeuffer A, Jalilzadeh S, Perz S, Mueller JC, Hinterseer M, Illig T, et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: Results from the KORA study. *Circ Res* 2005; **96**: 693–701.
- Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MWT, Miyamoto Y, et al. A common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. *Circulation* 2006; **113**: 338–344.

Clinical Aspects of Type-1 Long-QT Syndrome by Location, Coding Type, and Biophysical Function of Mutations Involving the KCNQ1 Gene

Arthur J. Moss, MD*; Wataru Shimizu, MD, PhD*; Arthur A.M. Wilde, MD, PhD*; Jeffrey A. Towbin, MD*; Wojciech Zareba, MD, PhD; Jennifer L. Robinson, MS; Ming Qi, PhD; G. Michael Vincent, MD; Michael J. Ackerman, MD, PhD; Elizabeth S. Kaufman, MD; Nynke Hofman, MSc; Rahul Seth, MD; Shiro Kamakura, MD, PhD; Yoshihiro Miyamoto, MD, PhD; Ilan Goldenberg, MD; Mark L. Andrews, BBA; Scott McNitt, MS

Background—Type-1 long-QT syndrome (LQTS) is caused by loss-of-function mutations in the KCNQ1-encoded I_{K1} cardiac potassium channel. We evaluated the effect of location, coding type, and biophysical function of KCNQ1 mutations on the clinical phenotype of this disorder.

Methods and Results—We investigated the clinical course in 600 patients with 77 different KCNQ1 mutations in 101 proband-identified families derived from the US portion of the International LQTS Registry (n=425), the Netherlands' LQTS Registry (n=93), and the Japanese LQTS Registry (n=82). The Cox proportional hazards survivorship model was used to evaluate the independent contribution of clinical and genetic factors to the first occurrence of time-dependent cardiac events from birth through age 40 years. The clinical characteristics, distribution of mutations, and overall outcome event rates were similar in patients enrolled from the 3 geographic regions. Biophysical function of the mutations was categorized according to dominant-negative (>50%) or haploinsufficiency (\leq 50%) reduction in cardiac repolarizing I_{K1} potassium channel current. Patients with transmembrane versus C-terminus mutations (hazard ratio, 2.06; $P<0.001$) and those with mutations having dominant-negative versus haploinsufficiency ion channel effects (hazard ratio, 2.26; $P<0.001$) were at increased risk for cardiac events, and these genetic risks were independent of traditional clinical risk factors.

Conclusions—This genotype–phenotype study indicates that in type-1 LQTS, mutations located in the transmembrane portion of the ion channel protein and the degree of ion channel dysfunction caused by the mutations are important independent risk factors influencing the clinical course of this disorder. (*Circulation*. 2007;115:2481-2489.)

Key Words: electrocardiography ■ genetics ■ long-QT syndrome

The hereditary long-QT syndrome (LQTS) is characterized by prolonged ventricular repolarization on the ECG and arrhythmia-related syncope and sudden death.¹ Mutations in 1 or more of several ion channel genes are known to cause this disorder,² with mutations in the KCNQ1 gene causing the type-1 long-QT syndrome.³⁻⁵ The KCNQ1 gene codes for the potassium channel protein responsible for the slow component of the delayed rectifier repolarizing current (I_{K1}). Mutations involving this gene result in reduction of the repolarizing I_{K1} current and lengthening of the QT interval.³

Clinical Perspective p 2489

Functional I_{K1} channels result from the coassembly of 4 subunits into a tetrameric protein channel that is transported to the myocyte membrane. Each subunit contains 6 membrane-spanning domains (S1 to S6) flanked by amino (N)- and carboxyl (C)-terminus regions. Two distinct biophysical mechanisms mediate the reduced I_{K1} current in patients with KCNQ1 mutations: (1) coassembly or trafficking defects in which mutant subunits are not transported

Received September 17, 2006; accepted March 2, 2007.

From the Cardiology Division (A.J.M., W.Z., J.L.R., I.G., M.L.A., S.M., R.S.) of the Department of Medicine and the Department of Pathology (M.Q.), University of Rochester School of Medicine and Dentistry, Rochester, NY; Division of Cardiology, Department of Internal Medicine (W.S., S.K.) and Laboratory of Molecular Genetics (Y.M.), National Cardiovascular Center, Suita, Japan; Departments of Clinical and Experimental Cardiology (A.A.M.W.) and Clinical Genetics (N.H.), Academic Medical Center, Amsterdam, the Netherlands; Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston (J.A.T.); School of Medicine, University of Utah, Salt Lake City (G.M.V.); Departments of Medicine, Pediatrics, and Molecular Pharmacology, Mayo Clinic College of Medicine, Rochester, Minn (M.J.A.); and Heart and Vascular Research Center, MetroHealth Campus of Case Western Reserve University, Cleveland, Ohio (E.S.K.).

*The first 4 authors contributed equally to this work.

The online-only Data Supplement, consisting of references, is available with this article at <http://circ.ahajournals.org/cgi/content/full/CIRCULATIONAHA.106.665406/DC1>.

Correspondence to Arthur J. Moss, MD, Heart Research Follow-Up Program, Box 653, University of Rochester Medical Center, Rochester, NY 14642-8653. E-mail heartajm@heart.rochester.edu

© 2007 American Heart Association, Inc.

Circulation is available at <http://www.circulationaha.org>

DOI: 10.1161/CIRCULATIONAHA.106.665406

properly to the cell membrane and fail to incorporate into the tetrameric channel, with the net effect being a $\leq 50\%$ reduction in channel function (haploinsufficiency)⁵; and (2) formation of defective channels involving mutant subunits with the altered channel protein transported to the cell membrane, resulting in a dysfunctional channel having $>50\%$ reduction in channel current (dominant-negative effect).⁶

Limited prior studies involving relatively small numbers of patients with type-1 LQTS have been reported with conflicting results on the relationship between various KCNQ1 mutations and the clinical outcome.^{7,8} We hypothesized that the location, coding type, and functional effect of the channel mutation would have important influence on the phenotypic manifestations and clinical course of patients with this disorder. To test this hypothesis, we investigated the clinical aspects of a large cohort of subjects having a spectrum of KCNQ1 mutations categorized by their location, coding type, and type of biophysical ion channel dysfunction.

Methods

Study Population

The study population of 600 subjects with genetically confirmed KCNQ1 mutations was derived from 101 proband-identified families with the type-1 LQTS disorder. The proband in each family had QTc prolongation not due to a known cause. The subjects were drawn from the US portion of the International LQTS Registry (n=425), the Netherlands' LQTS Registry (n=93), and the Japanese LQTS Registry (n=82). All subjects or their guardians provided informed consent for the genetic and clinical studies.

Phenotype Characterization

Routine clinical and ECG parameters were acquired at the time of enrollment in each of the registries. Follow-up was censored at age 41 years to avoid the influence of coronary disease on cardiac events. Measured parameters on the first recorded ECG included QT and R-R intervals in milliseconds, with QT corrected for heart rate by Bazett's formula. The QTc interval was expressed in its continuous form and categorized into 3 levels: $<.500$, $.500$ to $.530$, and $>.530$ ms. Clinical data were collected on prospectively designed forms with information on demographic characteristics, personal and family medical history, ECG findings, therapy, and end points during long-term follow-up. LQTS-related cardiac events included syncope, aborted cardiac arrest, or unexpected sudden death without a known cause. Data common to all 3 LQTS registries involving genetically identified patients with type-1 genotype were electronically merged into a common database for the present study.

Genotype Characterization

The KCNQ1 mutations were identified with the use of standard genetic tests performed in academic molecular-genetic laboratories including the Functional Genomics Center, University of Rochester Medical Center, Rochester, NY; Baylor College of Medicine, Houston, Tex; Mayo Clinic College of Medicine, Rochester, Minn; Boston Children's Hospital, Boston, Mass; Laboratory of Molecular Genetics, National Cardiovascular Center, Suita, Japan; and Department of Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands.

Genetic alterations of the amino acid sequence were characterized by location and by the specific mutation (missense, splice site, in-frame insertions/deletions, nonsense, stop codon, and frameshift). The transmembrane region of the KCNQ1-encoded channel was defined as the coding sequence involving amino acid residues from 120 through 355 (S5-pore-S6 region 285 to 355), with the N-terminus region defined before residue 120 and the C-terminus region after residue 355. Nineteen study patients had intron mutations predicted to disrupt the canonical splice-site domains. Fifty-one

subjects died of sudden cardiac death at a young age but did not have genotype studies. These 51 subjects were assumed to have the same KCNQ1 mutation as other affected members of their respective family. Twelve subjects had 2 mutations, one in the KCNQ1 gene and a second mutation in another LQTS ion channel gene; these 12 subjects are described separately and are not included in any of the tables or outcome analyses. Subjects with Jervell and Lange-Nielsen syndrome with deafness and 2 KCNQ1 mutations as well as those with 1 known KCNQ1 mutation and congenital deafness are not included in the present study.

The biophysical function of the mutant channels was classified as having dominant-negative effect ($>50\%$ reduction in function) or haploinsufficiency ($\leq 50\%$ reduction in function) on the basis of the following: (1) cellular expression studies for those with missense (n=21) and nonsense (n=2) mutations reported in the literature, with the functional information derived exclusively from heterologous expression studies; and (2) assumed loss of function for identified nonsense, splice site, in-frame deletion, and frameshift mutations (n=10) that have not yet been functionally characterized. Forty-one missense mutations and the 3 intron mutations that have not been functionally reported in cellular expression studies were categorized as unknown in terms of type of functional perturbation.

Statistical Analysis

Differences in the univariate characteristics by specific groupings were evaluated by standard statistical methods. The primary end point was time to syncope, aborted cardiac arrest, or sudden death, whichever occurred first. The cumulative probability of a first cardiac event was assessed by the Kaplan-Meier method with significance testing by the log-rank statistic. The Cox proportional hazards survivorship model was used to evaluate the independent contribution of clinical and genetic factors to the first occurrence of time-dependent cardiac events from birth through age 40 years.⁹ Stratified and unstratified Cox regression models, allowing for time-dependent covariates, were fit to estimate the adjusted hazard ratio of each factor as a predictor of first cardiac events. We observed that sex was not proportional as a function of age with crossover in risk at age 13 years on univariate Kaplan-Meier analysis. To relax the assumption of proportional hazards for sex over the entire age range, separate nonparametric baseline hazard functions were allowed for male and female subjects via the stratified Cox model; then, to summarize the sex effect, sex was modeled in an unstratified Cox model as a time-dependent covariate (via an interaction with time), allowing for different hazard ratios by sex before and after age 13 years.

Because almost all the subjects were first- and second-degree relatives of probands, the effect of lack of independence between subjects was evaluated in the Cox model with grouped jackknife estimates for family membership.¹⁰ All grouped jackknife standard errors for the covariate risk factors fell within 3% of those obtained from the unadjusted Cox model, and therefore only the Cox model findings are reported.

Patients who died suddenly at a young age from suspected LQTS and who did not have an ECG for QTc measurement were identified in the Cox models as "QTc missing." Prespecified covariate interactions were evaluated. The influence of time-dependent β -blocker therapy (the age at which β -blocker therapy was initiated) on outcome was determined by adding this variable to the final Cox model containing the various covariates.

The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results

Total Study Population

The spectrum and number of KCNQ1 mutations by location, type of mutation, and functional effect are presented in Table 1, with the location frequency of the mutations presented diagrammatically in Figure 1. A total of 77 different KCNQ1

TABLE 1. KCNQ1 Mutations by Location and Coding, Type of Mutation, and Functional Effect

Location and Coding*	No. of Subjects†	Type of Mutation	Functional Effect‡
N-terminus			
M1V	1	Missense	Unknown
G57V	1	Missense	Unknown
Transmembrane			
W120C	2	Missense	Unknown
T144A	7	Missense	Unknown
A150fs/133 [del CT 451-452]	2	Frameshift	Haploinsufficiency
E160K	3	Missense	Unknown
G168R	44	Missense	Unknown
Y171X [513 C.>G]	6	Nonsense	Haploinsufficiency
R174H	2	Missense	Unknown
A178P	5	Missense	Dominant-negative effect (a)
Y184S	18	Missense	Unknown
G185S	10	Missense	Unknown
G189E	2	Missense	Unknown
G189R	4	Missense	Dominant-negative effect (b)
R190Q	4	Missense	Haploinsufficiency (b, c)
L191fs/90 [del TGC GC 572-576]	8	Frameshift	Haploinsufficiency
R195fs/40 [del G 585]	2	Frameshift	Haploinsufficiency
S225L	13	Missense	Dominant-negative effect (d)
A226V	3	Missense	Unknown
R237P	1	Missense	Unknown
D242N	3	Missense	Unknown
R243C	13	Missense	Haploinsufficiency (e)
V254 mol/L	59	Missense	Dominant-negative effect (b, f)
R258C	1	Missense	Haploinsufficiency
R259C	1	Missense	Haploinsufficiency (g)
L266P	15	Missense	Unknown
G269D	35	Missense	Dominant-negative effect (h)
G269S	25	Missense	Haploinsufficiency (i)
L273F	6	Missense	Dominant-negative effect (a)
I274V	1	Missense	Unknown
S277L	3	Missense	Unknown
Y278H	2	Missense	Unknown
E284K	2	Missense	Unknown
G292D	3	Missense	Unknown
F296S	2	Missense	Unknown
G306R	2	Missense	Dominant-negative effect (b, j)
V310I	1	Missense	Unknown
T312I	14	Missense	Dominant-negative effect (a)
G314S	8	Missense	Dominant-negative effect (h, k, l, m)
Y315C	10	Missense	Dominant-negative effect (d, n)
Y315S	1	Missense	Dominant-negative effect (h, m)
D317G	3	Missense	Unknown
P320H	1	Missense	Unknown
T322 mol/L	2	Missense	Unknown
G325R	3	Missense	Unknown
delF340 [del CTT 1017-1019]	7	In-frame deletion	Haploinsufficiency
A341E	9	Missense	Dominant-negative effect (b)
A341V	20	Missense	Dominant-negative effect (o)

TABLE 1. Continued

Location and Coding*	No. of Subjects†	Type of Mutation	Functional Effect‡
P343S	1	Missense	Dominant-negative effect (p)
A344A/sp [1032 G>A]	27	Splice site	Haploinsufficiency
A344V	17	Missense	Unknown
S349W	15	Missense	Unknown
L353P	4	Missense	Unknown
C-terminus			
Q357H	3	Missense	Unknown
R360G	3	Missense	Unknown
S373P	7	Missense	Unknown
K393N	10	Missense	Unknown
R397W	5	Missense	Unknown
P400fs/62 [ins C 1201-1022]	6	Frameshift	Haploinsufficiency
P448fs/13 [ins G 1344-1345]	11	Frameshift	Haploinsufficiency
I517T	3	Missense	Unknown
R518X [1552 C>T]	11	Nonsense	Haploinsufficiency (q)
M520R	3	Missense	Unknown
V524G	4	Missense	Unknown
Q530X [1588 C>T]	13	Nonsense	Haploinsufficiency (q)
R562 mol/L	2	Missense	Unknown
S566F	3	Missense	Unknown
I567S	6	Missense	Unknown
S571fs/20 [dcl C 1714]	3	Frameshift	Haploinsufficiency
R591C	5	Missense	Unknown
R591H	6	Missense	Haploinsufficiency (r)
R594Q	11	Missense	Haploinsufficiency (q)
D611Y	10	Missense	Haploinsufficiency (s)
A636fs/28 [del C 1909]	2	Frameshift	Haploinsufficiency
Intron			
IVS2+1 G>A	2	Splice site	Unknown
IVS4+5 G>A	2	Splice site	Unknown
IVS7+5 G>A	15	Splice site	Unknown

*The numbers and letters refer to the amino acid coding of the mutant channel protein. The brackets contain the nucleotide code for deletions, frameshift, splice site, and nonsense mutations.

†Included in this table are 52 subjects who died suddenly at a young age. These subjects were from families with a known KCNQ1 mutation and were assumed to have their respective family mutation.

‡Dominant-negative effect is associated with >50% reduction whereas haploinsufficiency is associated with <50% reduction in ion channel repolarizing current. See text for details. Letters in parentheses refer to references that are available in the online-only Data Supplement.

mutations were identified. A majority of the mutations were localized to the S1 to S6 transmembrane domains (66%), and missense (single amino acid substitutions) accounted for 81% of all the mutations.

The phenotypic characteristics of patients enrolled in each of the 3 registries and by location and type of mutation are presented in Table 2. The clinical characteristics of the patients were similar among the 3 registries except for QTc duration and frequency of β -blocker use. The QTc interval was longer and cardiac events and β -blocker use were more frequent in patients with mutations in the transmembrane than in the C-terminus location. β -Blockers were used less frequently in patients from the Japanese registry than in patients from the other 2 registries. The frequency of first cardiac

events was higher in those with than without missense mutations. The clinical characteristics of the 19 subjects possessing intron mutations resembled those with transmembrane and missense mutations.

The QTc interval was significantly longer in the 12 patients with 2 mutations than in those with only single KCNQ1 mutations (570 ± 70 versus 480 ± 60 ms; $P < 0.01$). All 12 patients with 2 mutations experienced at least 1 cardiac event.

The cumulative probabilities of first cardiac event by location and type of mutation are presented in Figure 2A and 2B, respectively. Significantly higher event rates were found in subjects with transmembrane than C-terminus mutations and in those with than without missense mutations, with the most rapid increase in event rates occurring during ages 7 to

Subjects

N-terminus: 2
 Transmembrane: 452
 C-terminus: 127

Mutations in the KCNQ1 Channel




Figure 1. Frequency and location of 74 different mutations in the KCNQ1 potassium channel involving 581 subjects. The 19 subjects with 3 intron mutations are not included in this diagram. The α sub-unit involves the N-terminus (N), 6 membrane-spanning segments, and the C-terminus portion (C). The size of the circles reflect the number of subjects with mutations at the respective locations, with the small circles indicating <15, medium-sized circles 15 to 30, and large circles >30 subjects.

20 years. In patients with transmembrane-localized mutations, the event rates for patients with mutations localized to the pore region (S5-pore-S6) were nearly identical to those with nonpore mutations (data not shown).

The findings from the Cox regression analysis for location and type of mutation are presented in Table 3. The clinical risk factors associated with first cardiac events involved males before age 13 years, females after age 13

TABLE 2. Phenotypic Characteristics by Source of Subjects, Location of Mutation, and Type of Mutation

Characteristics	Source of Subjects			Location of Mutation		Missense Mutation		Intron Mutation (n=19)
	United States (n=425)	Netherlands (n=93)	Japan (n=82)	Trans Membrane (n=452)	C-Terminus (n=127)	Yes (n=483)	No (n=98)	
Female, %	57	53	54	57	51	54	62	63
EKG at enrollment								
QTc†‡, ms	488 ± 58	450 ± 45	472 ± 46	485 ± 53	460 ± 61	481 ± 59	471 ± 38	478 ± 60
Therapy, %								
β-Blockers†‡	45	34	26	45	28	42	38	37
Pacemaker	2.4	0	0	1.5	2.4	1.4	3.1	0
Sympathectomy	0.5	0	0	0.4	0	0.4	0	0
Defibrillator	6.4	3.2	0	5.8	3.1	5.2	5.1	0
First cardiac event*†§, %								
Syncope‡ (n=200)	35	31	29	38	17	36	21	32
Aborted cardiac arrest (n=15)	1.9	1.1	7.3	2.9	0.8	2.5	2.0	5.3
Death (n=23)	4.0	5.5	1.2	4.0	3.1	4.2	2.0	5.3
Ever cardiac event, %								
Syncope‡§	35	31	31	39	17	37	21	33
Aborted cardiac arrest†	2.4	15	8.8	5.3	3.2	5.4	2.0	11
Death	11	14	2.4	10	6.3	11	4.1	26

Plus-minus values are mean ± SD. Percentages >10 are rounded to a whole number. The 600 subjects in this table include 51 subjects who died suddenly at a young age, were from families with known KCNQ1 mutation, and were assumed to have the family mutation. Patients with intron mutations are categorized separately and are not included in the location or missense categories. Seven subjects with transmembrane mutations and 1 with C-terminus mutations had missing data about the date of the first cardiac event. Eight subjects with missense mutations had missing data about the date of the first cardiac event. Numbers in parentheses indicate the total number of specific first cardiac events from the 3 sources of patients.

*First cardiac event was syncope, aborted cardiac arrest, or sudden death, whichever occurred first.

†P<.01 for the comparison of characteristics among the 3 sources of subjects.

‡P<.01 for the comparison of characteristics between the 2 locations of the mutations.

§P<.01 for the comparison of characteristics between missense yes and no.




Figure 2. Kaplan-Meier estimate of the cumulative probability of a first cardiac event by location (A), type (B), and biophysical function of the mutation (C).

years, and longer QTc intervals. Mutations located in the transmembrane region of the channel made significant and independent contributions to the risk model, but missense mutations were not an independent risk factor. Three different intron mutations were present in 19 subjects from 4 families, and these intron mutations made a meaningful but nonsignificant contribution to the risk model. Prespecified interactions were investigated for their effect on cardiac events, and no significant interactions were found for transmembrane location by type of mutation, transmembrane location by QTc, or mutation type by QTc. Time-dependent β -blocker use was associated with a significant 74% reduction in the risk of first cardiac events ($P < 0.001$).

TABLE 3. Cox Regression With Multiple Predictor Variables Including Location and Type of Mutations for First Cardiac Event

Variable	Hazard Ratio	95% CI	P
Netherlands:United States	1.15	0.74–1.78	0.55
Japan:United States	1.45	0.98–2.16	0.07
Male <13 y:female <13 y	1.72	1.25–2.38	<0.001
Female 13–40 y:male 13–40 y	2.27	1.30–3.96	<0.01
QTc 500–530 ms:QTc <500 ms	2.04	1.41–2.96	<0.001
QTc >530 ms:QTc <500 ms	3.25	2.25–4.69	<0.001
QTc missing*:QTc <500 ms	2.26	1.57–3.25	<0.001
Transmembrane:C-terminus	2.06	1.36–3.12	<0.001
Missense yes:no	1.33	0.86–2.05	0.20
Intron:C-terminus	2.45	0.98–6.11	0.06
Time-dependent β -blocker use	0.26	0.14–0.49	<0.001

The Cox analysis involved 592 subjects with 445 transmembrane, 126 C-terminus, 2 N-terminus, and 19 intron mutations; 8 subjects were not included in this Cox analysis because of missing data about the date of their first cardiac event.

*QTc missing category involves 47 subjects who died suddenly at a young age without a prior ECG.

Biophysical Function and Outcome

The clinical implications of disordered biophysical function of the mutant KCNQ1 channels were investigated in a subset of 356 subjects with known or suspected alteration in ion channel function (see Methods for functional categorization). The clinical characteristics of patients with dominant-negative and haploinsufficiency ion channel dysfunction are presented in Table 4. Patients with mutations having dominant-negative ion current effects had a longer QTc interval and a higher frequency of cardiac events than subjects with mutations resulting in haploinsufficiency. The cumulative probabilities of a first cardiac event by the biophysical function of the mutations are presented in Figure 2C. As shown in Table 5, patients with mutations having

TABLE 4. Phenotypic Characteristics by Biophysical Function of the KCNQ1 Mutations in 356 Subjects

Characteristics	Dominant-Negative Effect (n=187)	Haploinsufficiency (n=169)
Female, %	51	61
ECG at enrollment		
QTc,* ms	500±60	470±50
Therapy, %		
β -Blockers	47	37
Pacemaker	1.1	4.1
Sympathectomy	0.5	0
Defibrillator	4.8	7.7
First cardiac event*, %	53	27
Syncope	45	22
Aborted cardiac arrest	2.1	3.0
Death	5.3	2.4

Percentages >10 are rounded to a whole number. Two subjects had missing data about the date of their first cardiac event.

*P < 0.01.

TABLE 5. Cox Regression With Multiple Predictor Variables Including Ion Channel Dysfunction for First Cardiac Events

Variable	Hazard Ratio	95% CI	P
Netherlands:United States	2.78	1.48-5.23	<0.01
Japan:United States	1.63	1.02-2.63	0.04
Male <13 y:female <13 y	1.94	1.29-2.91	<0.01
Female 13-40 y:male 13-40 y	1.95	0.99-3.87	0.06
QTc 500-530 ms:QTc <500 ms	1.88	1.18-2.99	<0.01
QTc >530 ms:QTc <500 ms	3.22	2.06-5.05	<0.001
QTc missing*:QTc <500 ms	2.07	1.29-3.33	<0.01
Dominant-negative:haploinsufficiency	2.26	1.56-3.25	<0.001
Time-dependent β -blocker use	0.21	0.09-0.48	<0.001

The analysis involved 354 subjects with known or suspected ion channel dysfunction; 2 subjects were not included because of missing data about the date of their first cardiac event.

*The QTc missing category involves 26 patients who died suddenly at a young age without a prior ECG.

dominant-negative functional effects experienced a significantly greater risk for cardiac events than those with haploinsufficiency (hazard ratio, 2.26; 95% CI, 1.56 to 3.25; $P<0.001$) after adjustment for relevant covariates including QTc and gender effects by age group. β -Blocker use was associated with a significant 79% reduction in first cardiac events in this subset of patients. Because substantial collinearity exists for transmembrane mutations, missense mutations, and mutations with dominant-negative biophysical function, the individual effects of these 3 mutation parameters could not be ascertained reliably in the same Cox model.

Discussion

The main results of the present study from 600 patients having a spectrum of KCNQ1 mutations derived from 3 LQTS registries are significantly higher cardiac event rates in patients with transmembrane mutations and in patients with mutations having a putative dominant-negative effect on the repolarizing I_K current. The effect of these genetically determined factors is independent of traditional clinical risk factors and of β -blocker therapy.

Since 1995, when the first 2 genes responsible for LQTS were identified,^{11,12} molecular genetic studies have revealed a total of 9 forms of congenital LQTS caused by mutations in genes involving potassium channel (LQT-1, -2, -5, -6, and -7), sodium channel (LQT-3, -9), and calcium channel proteins (LQT-8) as well as a membrane-adaptor protein (LQT-4).²⁻¹¹ Genotype-phenotype studies have enabled us to stratify risk and to treat more specifically patients with LQT-1, LQT-2, and LQT-3 subtypes of this genetic disorder. LQT-1, the most common form of LQTS, accounts for $\approx 50\%$ of genotyped patients^{4,14} and has more variable expressivity and incomplete penetrance than the other forms.¹⁵ Mutation location and knowledge of the functional effects of the mutation provide additional risk information beyond the clinical risk factors and the genotype, at least for LQT-1, and this information should contribute to improved risk stratification and more focused management of these higher-risk patients.

Mutations in KCNQ1 are responsible for defects in the slowly activating component of the delayed rectifier current I_{Ks} .¹⁶ This current is the main repolarizing current at increased heart rate and is highly sensitive to catecholamines.⁴ We speculate that I_{Ks} channels with transmembrane mutations might have reduced responsiveness to the regulatory β -adrenergic signaling of the ion-conduction pathway with more impairment of shortening of the QTc with exercise-related tachycardia than mutations in the C-terminus region.

Functional I_{Ks} channels result from the coassembly of 4 KCNQ1-encoded subunits. A mutated gene encodes a protein with aberrant function, and the presence of both normal and abnormal proteins in the ion channel contributes to a $\geq 50\%$ reduction in ion channel function (dominant-negative effect). An alternative mechanism of reduced repolarizing KCNQ1 K^+ current is the inability of mutated subunits to coassemble with normal gene products, such as occurs with a trafficking defect, resulting in a $\leq 50\%$ reduction in channel function (haploinsufficiency). With only 1 exception,¹⁷ this is the case for all studied truncating mutations leading to incomplete proteins. Our assumption that truncated proteins (based on frameshift nonsense mutations) lead to haploinsufficiency seems justified. The biophysical effect of missense mutations is unpredictable, and both haploinsufficiency and dominant-negative effects have been described. In the absence of reported biophysical studies, missense mutations were classified as unknown.

Previous attempts to identify a genotype-phenotype relationship for KCNQ1 mutations failed to reach consensus on the clinical outcome of the type and site of mutations.^{7,8} Relatively small numbers and different ethnic background of the previously reported patients with the LQT-1 genotype might be responsible for the discrepant results. The present larger study allows us to demonstrate for the first time that the biophysical effect clearly affects the clinical outcome (ie, dominant-negative mutations are associated with a more severe phenotype than are mutations conferring haploinsufficiency [Figure 2C], even after adjustment for relevant covariates [Table 5]). The risk observed in 19 subjects with 3 different intron mutations was not quite significant ($P=0.06$), possibly because of small numbers, but the magnitude of the risk effect was similar to the risk accompanying transmembrane mutations. Although these intron mutations produced splice-site alterations predicted to affect the transmembrane portion of the ion channel, we used a separate categorization of intron mutations in view of the limited understanding of the structural alterations and functional effects resulting from these exon-skipping intron mutations.

A few additional findings from this large genotype-phenotype study of type-1 LQTS patients emphasize high risk for first cardiac events during adolescence, a crossover in risk by sex at approximately age 13 years, and a lower rate of first cardiac events in the adult years than in the younger years. These findings are not especially new,^{18,19} but the present study highlights their presence in type-1 LQTS.

Study Limitations

The present study used the biophysical function of mutations reported in the literature in only a portion of the mutations

that were included (see references associated with Table 1 in the online-only Data Supplement). The published studies were from many different laboratories with the use of different cellular heterologous expression systems involving *Xenopus* oocytes and other cells at both room and physiological temperatures. Although such nonuniform testing may have contributed to some inconsistency in the categorized biophysical function, the finding of a significantly higher event rate in mutations with dominant-negative than with haploinsufficient effects (hazard ratio, 2.26; $P < 0.001$) is unlikely to have resulted from the nonuniform testing. Unfortunately, we did not have the resources to perform such uniform testing in all 77 mutations presented in the present study.

Once a mutation was identified in KCNQ1, thorough genetic sequencing was not performed routinely in all the ion channel genes to look for second mutations. Thus, some of the patients included in the analysis may have had a second mutation in addition to the identified KCNQ1 mutation. It is estimated that $\approx 10\%$ of genotype LQTS patients may carry a second mutation, and those with >1 mutation could contribute to some of the findings in our study. In addition, it is possible that some of the reported mutations (Table 1) are simply uncommon sequence mutations, but this is relatively unlikely because all the subjects in the present study were derived from families in which the proband had QTc prolongation not due to a known cause.

The outcome analyses included subjects from families with a known KCNQ1 mutation who died suddenly and unexpectedly at a young age and were classified as LQTS-related death with the same mutation that was present in the family. It is possible that a few of these subjects could have died from a non-LQTS cause or had an LQTS mutation different from the family mutation, but we think the error rate is likely to be small. The number of deaths and aborted cardiac arrest events is small, and there is insufficient power to evaluate the risk association of the genotype characteristics with these endpoint events in a multivariate time-dependent model.

Conclusions

The present study confirms that in patients with type-I LQTS, longer QTc intervals are associated with higher cardiac event rates and that male patients are generally younger than female patients at first cardiac events.^{20,21} The new findings from the present study are that transmembrane mutations and mutations with dominant-negative functional effect adversely influence the outcome of this disorder independent of traditional clinical risk factors and β -blocker therapy. The present study was not designed to assess the effectiveness of different therapies in patients with KCNQ1 mutations. The findings presented do not provide justification for using specific genotype characteristics to identify patients for implanted defibrillator therapy.

Note Added in Proof

After this article was accepted for publication, we noted the recent article by Tsuji et al. in which the A344A/sp [1032G>A] mutation that we categorized as haploinsufficient (Table 1) was reported to have a weak dominant-

negative effect.²² We reran the KCNQ1 data recategorizing the 27 A344A/sp [1032 G>A] mutations as dominant-negative. Negligible changes occurred in the results as presented in Table 5 and Figure 2C: the hazard ratio for dominant-negative:haploinsufficiency (Table 5) was unchanged at 2.26 ($P < 0.001$).

Acknowledgment

We thank David J. Tester, Senior Research Technologist, Sudden Death Genomics Laboratory, Mayo Clinic College of Medicine, Rochester, Minn, for the detailed review and assistance he provided on the terminology and nomenclature for the annotated mutations presented in Table 1.

Sources of Funding

This study was supported in part by (1) research grants HL-33843 and HL-51618 from the National Institutes of Health, Bethesda, Md (Dr Moss); (2) Ministry of Education, Culture, Sports, Science, and Technology Leading Project for Biosimulation and health sciences research grant (H18-Research on Human Genome-002) from the Ministry of Health, Labor, and Welfare, Japan (Dr Shimizu); (3) grant 2000.059 from the Nederlandse Hartstichting, Amsterdam, the Netherlands (Dr Wilde); and (4) research grants from the National Institutes of Health (HD42569), American Heart Association (Established Investigator Award), CJ Foundation for SIDS, and Dr Scholl Foundation (Dr Ackerman).

Disclosures

Dr Ackerman is a consultant for Clinical Data (formerly Genesance Pharmaceuticals) with respect to the FAMILION genetic test for cardiac ion channel mutations. The other authors report no conflicts.

References

- Moss AJ. Long QT syndrome. *JAMA*. 2003;289:2041–2044.
- Wilde AA, Bezzina CR. Genetics of cardiac arrhythmias. *Heart*. 2005; 91:1352–1358.
- Sanguinetti MC. Long QT syndrome: ionic basis and arrhythmia mechanism in long QT syndrome type 1. *J Cardiovasc Electrophysiol*. 2000;11:710–712.
- Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. *Heart Rhythm*. 2005;2:507–517.
- Bianchi L, Priori SG, Napolitano C, Surewicz KA, Dennis AT, Memmi M, Schwartz PJ, Brown AM. Mechanisms of I(Ks) suppression in LQT1 mutants. *Am J Physiol*. 2000;279:H3003–H3011.
- Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Blana MA. Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. *Circulation*. 1997;96: 1733–1736.
- Zareba W, Moss AJ, Shew G, Kaufman ES, Priori S, Vincent GM, Towbin JA, Benhorin J, Schwartz PJ, Napolitano C, Hall WJ, Keating MT, Qi X, Robinson JL, Andrews ML. Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome. *J Cardiovasc Electrophysiol*. 2003;14:1149–1153.
- Shimizu W, Horie M, Ohno S, Takenaka K, Yamaguchi M, Shimizu M, Washizuka T, Aizawa Y, Nakamura K, Ohe T, Aiba T, Miyamoto Y, Yoshinasa Y, Towbin JA, Priori SG, Kamakura S. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. *J Am Coll Cardiol*. 2004;44:117–125.
- Cox DR. Regression models and life-tables. *J Stat Soc [B]*. 1972;34: 187–220.
- Therneau TM, Grambsch PM. *Modeling Survival Data: Extending the Cox Model*. New York, NY: Springer-Verlag; 2000.
- Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. *Cell*. 1995;81:299–307.
- Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. Cardiac sodium channel mutations in patients with long QT

- syndrome, an inherited cardiac arrhythmia. *Hum Mol Genet*. 1995;4:1603-1607.
13. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. *Circulation*. 2006;114:2104-2112.
 14. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. *Circulation*. 2000;102:1178-1185.
 15. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, Suyama K, Aihara N, Sunagawa K, Echigo S, Miyamoto Y, Yoshimasa Y, Nakamura K, Ohe T, Towbin JA, Priori SG, Kamakura S. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. *Heart Rhythm*. 2004;1:276-283.
 16. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of Kv1L1/QT1 and minK (hK) proteins to form cardiac I(Ks) potassium channel. *Nature*. 1996;384:80-83.
 17. Aizawa Y, Ueda K, Wu LM, Inagaki N, Hayashi T, Takahashi M, Ohta M, Kawano S, Hirano Y, Yasunami M, Kimura A, Hiraoka M. Truncated KCNQ1 mutant, A178fs/105, forms hetero-multimer channel with wild-type causing a dominant-negative suppression due to trafficking defect. *FEBS Lett*. 2004;574:145-150.
 18. Hobbs JB, Peterson DR, Moss AJ, McNitt S, Zareba W, Goldenberg J, Qi M, Robinson JL, Sauer AJ, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Towbin JA, Vincent GM, Zhang L. Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. *JAMA*. 2006;296:1249-1254.
 19. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weikamp L, Vincent GM, Garson A Jr. The long QT syndrome: prospective longitudinal study of 328 families. *Circulation*. 1991;84:1136-1144.
 20. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. *Circulation*. 1998;97:2237-2244.
 21. Zareba W, Moss AJ, Locati EH, Lehmann MH, Peterson DR, Hall WJ, Schwartz PJ, Vincent GM, Priori SG, Benhorin J, Towbin JA, Robinson JL, Andrews ML, Napolitano C, Timothy K, Zhang L, Medina A. Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. *J Am Coll Cardiol*. 2003;42:103-109.
 22. Tsuji K, Akao M, Ishii TM, Ohno S, Makiyama T, Takenaka K, Doi T, Haruna Y, Yoshida H, Nakashima T, Kita T, Horie M. Mechanistic basis for the pathogenesis of long QT syndrome associated with a common splicing mutation in KCNQ1 gene. *J Mol Cell Cardiol*. 2007;42:662-669.

CLINICAL PERSPECTIVE

Type-1 long-QT syndrome is caused by loss-of-function mutations in the KCNQ1-encoded I_{Ks} cardiac potassium channel. In the present study involving 600 patients having a spectrum of KCNQ1 mutations derived from 3 long-QT syndrome registries, we found that cardiac event rates are increased significantly in patients with mutations located in the transmembrane region of the potassium channel and in patients with mutations having a putative dominant-negative effect on the repolarizing I_{Ks} current. The effects of these genetically determined factors are independent of traditional clinical risk factors and of β -blocker therapy. Mutation location and knowledge of functional effects of the mutation provide additional risk information beyond the clinical risk factors and the genotype, at least for type-1 long-QT syndrome, and this information should contribute to improved risk stratification and more focused management of these higher-risk patients.

Diagnostic and Prognostic Value of a Type 1 Brugada Electrocardiogram at Higher (Third or Second) V_1 to V_2 Recording in Men With Brugada Syndrome

Koji Miyamoto, MD, Miki Yokokawa, MD, Koji Tanaka, MD, Takayuki Nagai, MD, Hideo Okamura, MD, Takashi Noda, MD, PhD, Kazuhiro Satomi, MD, PhD, Kazuhiro Suyama, MD, PhD, Takashi Kurita, MD, PhD, Naohiko Aihara, MD, Shiro Kamakura, MD, PhD, and Wataru Shimizu, MD, PhD*

To evaluate the diagnostic and prognostic value of an electrocardiogram (ECG) recorded at a higher (third or second) intercostal space, 98 men (17 to 76 years of age, mean \pm SD 47 ± 13 ; with documented ventricular fibrillation [VF] in 22 and syncope in 32) were categorized into 3 groups; 68 men had a spontaneous type 1 ECG in standard leads V_1 and V_2 (S group), 19 had a spontaneous type 1 ECG only in the higher V_1 and V_2 leads (H group), and 11 had a type 1 ECG only after receiving class Ic sodium channel blockers (Ic group). There were no significant differences in baseline clinical characteristics, including VF episodes, syncope, atrial fibrillation, family history, late potentials, and inducibility of VF during electrophysiologic study across the 3 groups. During prospective follow-up periods (779 ± 525 , 442 ± 282 , and 573 ± 382 days, respectively), subsequent cardiac events occurred in 11 men (16%) within the S group, in 2 men (11%) in the H group, and in 0 men (0%) in the Ic group ($p = \text{NS}$, S vs H group). In men with previous episodes of VF, subsequent cardiac events occurred in 7 (44%) within the S group and in 2 (50%) in the H group ($p = \text{NS}$). In conclusion, men with a spontaneous type 1 Brugada ECG recorded only at higher leads V_1 and V_2 showed a prognosis similar to that of men with a type 1 ECG in using standard leads V_1 and V_2 . © 2007 Elsevier Inc. All rights reserved. (Am J Cardiol 2007;99:53–57)

Brugada syndrome is characterized by a high risk of sudden cardiac death due to ventricular fibrillation (VF) and a specific ST-segment elevation in the right precordial leads (V_1 to V_3) in the absence or presence of sodium channel blockers.^{1,2} Recent consensus reports have proposed 3 types of ST-segment elevation (types 1 to 3) in this syndrome.^{3–5} Although the magnitude and pattern of ST-segment elevation differ in each patient and can change even in the same patient,^{6–8} documentation of a spontaneous type 1 electrocardiogram (ECG), which is defined as a coved type and a J-point elevation ≥ 0.2 mV, has been associated with a high risk of sudden cardiac death.^{3–5,9–11} Electrocardiographic recording in leads V_1 and V_2 at a higher (third or second) intercostal space has been reported to unmask or confirm a type 1 Brugada ECG, with a high sensitivity in individuals with suspected Brugada syndrome.^{12–14} However, system-

atic evaluation of recording leads V_1 and V_2 at a higher space, especially with regard to diagnostic and prognostic values, has not been done. This study evaluated the diagnostic and prognostic value of documentation of a spontaneous type 1 Brugada ECG in leads V_1 and V_2 recorded at a higher intercostal space.

Methods

The study population consisted of 98 probands from 98 unrelated families in whom a type 1 Brugada ECG was documented in leads V_1 and V_2 at a standard (fourth) and/or higher (third or second) intercostal space in the absence or presence of class Ic sodium channel blockers. They were enrolled between October 2000 and September 2004 and were followed prospectively. All 98 patients were men. Their average age at enrollment was 47 ± 13 years (17 to 76). VF had been documented in 22 men and 32 had shown only syncope. An SCN5A coding region mutation was identified in 8 men. Physical examination showed no abnormal findings, and no evidence of structural heart disease was demonstrated by echocardiogram in any subject. Informed consent was obtained from all subjects.

The 98 men were categorized into 3 groups; 68 had a spontaneous type 1 Brugada ECG recorded at a standard (fourth) intercostal space in leads V_1 and V_2 (S group), 19 had a spontaneous type 1 Brugada ECG recorded only at a higher (third or second) intercostal space in leads V_1 and V_2 (H group), and 11 had a type 1 Brugada ECG recorded only

Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, Osaka, Japan. Manuscript received June 2, 2006; revised manuscript received and accepted July 25, 2006.

Dr. Shimizu was supported by the Hoansha Research Foundation, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science and Technology Leading Project for Biosimulation, and Health Sciences Research Grants (H18, Research on Human Genome, 002) from the Ministry of Health, Labour and Welfare, Tokyo, Japan.

*Corresponding author: Tel: 81-6-6833-5012; fax: 81-6-6872-7486.

E-mail address: wshimizu@hsp.nccvc.go.jp (W. Shimizu).




Figure 1. Twelve-lead ECG in representative subjects of the 3 groups. (A) S group (spontaneous). A type 1 coved-type ST-segment elevation was seen at a standard (fourth) intercostal space in leads V₁ and V₂ (arrows) at baseline. (B) H group (spontaneous). A type 1 Brugada ECG was recorded at higher (third and second) intercostal spaces in leads V₁ and V₂ (V₃) (arrows) but not at a standard (fourth) intercostal space in these leads at baseline. (C) Ic group. A type 1 Brugada ECG was recorded at a standard (fourth) intercostal space in leads V₂ only after injection of 30 mg of pilsicainide.

Table 1

Comparison of clinical, electrocardiographic, and electrophysiologic characteristics across the 3 groups (S group vs H group vs Ic group)

Variable	S Group (only spontaneous) (n = 68)	H Group (only spontaneous) (n = 19)	Ic Group (n = 11)	p Value
Age (yrs) (range)	48 ± 16 (21–76)	46 ± 15 (17–72)	44 ± 16 (17–62)	0.64
Symptomatic	40 (59%)	7 (37%)	7 (64%)	0.20
Documented VF	16 (24%)	4 (21%)	2 (18%)	0.91
Syncope only	24 (35%)	3 (16%)	5 (45%)	0.17
Inducible VF/ventricular tachycardia	42 (78%)	6 (55%)	7 (70%)	0.27
Family history	14 (21%)	2 (11%)	3 (27%)	0.48
Presence of late potential	46 (74%)	11 (65%)	6 (55%)	0.59
Presence of atrial fibrillation	16 (24%)	3 (16%)	1 (9%)	0.47
Follow-up (d)	779 ± 525	442 ± 282	573 ± 382	<0.01*

* S group versus H group.

after receiving class Ic sodium channel blockers at standard and/or higher spaces in leads V₁ and V₂ (Ic Group) (Figure 1). We compared clinical, electrocardiographic, and electrophysiologic characteristics, and subsequent occurrence of cardiac events across the 3 groups.

Twelve-lead electrocardiographic data were recorded at a paper speed of 25 mm/s during sinus rhythm in a supine state at rest. Leads V₁ and V₂ were recorded at standard (fourth) and higher (third and second) intercostal spaces. At enrollment and categorization of subjects into 3 groups, ≥3 separate recordings of 12-lead ECGs were reviewed in each subject. If a spontaneous type 1 Brugada ECG was recorded at a standard space in leads V₁ and V₂ ≥1 time among multiple ECGs, the subject was classified into the S group. Similarly, if a spontaneous type 1 Brugada ECG was recorded at a higher space in leads V₁ and V₂ ≥1 time but not at all in standard leads V₁ and V₂, the subject was classified into the H group.

Drug challenge testing was performed with intravenous pilsicainide (1 mg/kg, maximum 50 mg, 5 mg/min) and/or flecainide (2 mg/kg, maximum 100 mg, 10 mg/min). The

test result was considered positive if a type 1 Brugada ECG appeared in >1 precordial lead.

Late potential was analyzed using a signal-averaged electrocardiographic system (Arrhythmia Research Technology 1200EPX, Milwaukee, Wisconsin). Three parameters were assessed using a computer algorithm: (1) total filtered QRS duration, (2) root-mean-square voltage of the terminal 40 ms of the filtered QRS complexes, and (3) duration of low-amplitude signals <40 μV of the filtered QRS complex. Late potential was considered present when a root-mean-square voltage <18 μV and a duration >38 ms were present.

An electrophysiologic study was conducted without antiarrhythmic drugs after informed consent was obtained. Programmed electrical stimulation was performed from the right ventricular apex and the right ventricular outflow tract with up to 3 extrastimuli. Induction of VF requiring direct cardioversion or nonsustained polymorphic ventricular tachycardia lasting ≥15 beats was considered a positive result.

All men were followed up at outpatient clinics of the National Cardiovascular Center. The end point was VF

documented in the storage memory of an implantable cardioverter-defibrillator, apparent syncope, or sudden cardiac death.

Quantitative values were expressed as mean \pm SD. Statistical significance in differences was analyzed by chi-square test or 1-way analysis of variance across the 3 groups (S vs H vs Ic group). A p value <0.05 was considered statistically significant. Survival curves were plotted using Kaplan-Meier methods and analyzed by log-rank test.

Results

Table 1 presents a comparison of clinical, electrocardiographic, and electrophysiologic characteristics across the S group (spontaneous only), H group (spontaneous only), and Ic group. There were no significant differences in baseline clinical characteristics with respect to gender, age, frequency of documented episodes of VF and syncope, family history (sudden cardiac death or a Brugada ECG), late potential, atrial fibrillation, and inducibility of VF/ventricular tachycardia during the electrophysiologic study across the 3 groups.

In all 68 men in the S group, a spontaneous type 1 Brugada ECG was always seen at a higher space in leads V_1 and V_2 on all ECGs showing a spontaneous type 1 Brugada ECG at a standard space in leads V_1 and V_2 . Ten of 68 men (15%) in the S group always showed a type 1 Brugada ECG at a standard space in leads V_1 and V_2 on multiple ECGs. However, the remaining 58 men (85%) did not always show a type 1 Brugada ECG at a standard position, and 30 of these (52%) always showed a type 1 Brugada ECG at a higher space in leads V_1 and V_2 . Of the 19 men in the H group, 7 (37%) always showed a type 1 Brugada ECG at a higher space in leads V_1 and V_2 . In the 11 patients in the Ic group, 8 (73%) showed a type 1 Brugada ECG after class Ic drugs at a standard space in leads V_1 and V_2 , and 3 (27%) showed this only at a higher space in leads V_1 and V_2 .

An implantable cardioverter-defibrillator was implanted in 47 of the 68 subjects (69%) in the S group (VF in 14 of 16, 88%; syncope only in 19 of 24, 79%; asymptomatic in 14 of 28, 50%), in 7 of the 19 subjects (37%) in the H group (VF in 4 of 4, 100%; syncope only in 1 of 3, 33%; asymptomatic in 2 of 12, 17%), and 7 of the 11 subjects (64%) in the Ic group (VF in 2 of 2, 100%; syncope only in 3 of 5, 60%; asymptomatic in 2 of 4, 50%). Three subjects (4%) in the S group and 1 (5%) in the H group were treated with antiarrhythmic drugs only (2 with amiodarone and 1 with disopyramide in the S group and 1 with atenolol in the H group).

The mean prospective follow-up period was 779 ± 525 days in the S group, 442 ± 282 days in the H group, and 573 ± 382 days in the Ic group. The follow-up period was significantly longer in the S group than in the H group ($p < 0.01$; Table 1). This difference was explained by the fact that more men were enrolled unintentionally in the S group soon after the prospective study was started.

Kaplan-Meier analysis of subsequent cardiac events during follow-up in the 3 groups is shown in Figure 2.




Figure 2. Kaplan-Meier analysis of subsequent cardiac events (VF in implantable cardioverter-defibrillator storage or sudden cardiac death) in the S group (spontaneous) (dashed line), H group (spontaneous) (solid line), and Ic group (dotted line) for (A) all patients, (B) symptomatic patients with previous VF and/or syncope, and (C) patients with previously documented VF.

Subsequent cardiac events occurred in 11 of 68 subjects (16%) in the S group (VF in implantable cardioverter-defibrillator storage in 9, sudden cardiac death in 2), 2 of 19 subjects (11%) in the H group (VF in implantable cardioverter-defibrillator storage in 2), but 0 of 11 subjects (0%) in the Ic group (Figure 2). No significant difference was observed in the frequency of cardiac events between the S and H groups.

Of the 13 men with subsequent cardiac events, 9 (69%) had previous VF (7 in the S group, 2 in the H group), 2 (15%) had previous syncope only (2 in the S group), and 2 (15%) were asymptomatic (2 in the S group) at enrollment. Because previous VF and/or syncope are strong indicators of subsequent cardiac events,^{9,10,15} the frequency of subsequent cardiac events was evaluated when the subjects were limited to symptomatic patients with previous VF and/or syncope. No significant difference was observed in the frequency of subsequent cardiac events between 40 symptomatic subjects in the S group and 7 symptomatic subjects in the H group (23%, 9 of 40, vs 29%, 2 of 7; Figure 2).

When the subjects were limited to patients with previous VF (16 in the S group, 4 in the H group), there was no significant difference in the frequency of subsequent cardiac events between the 2 groups (44%, 7 of 16, vs 50%, 2 of 4; Figure 2).

Of the 19 subjects in the H group, 14 underwent a drug challenge test, and 2 showed a type 1 Brugada ECG at a standard space in leads V₁ and V₂ after the test.

Discussion

The major findings of our study were that (1) recording at a higher space in leads V₁ and V₂ had higher sensitivity than that at a standard space in these leads in detecting a type 1 Brugada ECG and (2) a type 1 Brugada ECG recorded only at a higher space in leads V₁ and V₂ showed a similar prognostic value for subsequent cardiac events as that recorded at a standard space in these leads.

Priori et al⁹ reported that only 50% of patients with Brugada syndrome in whom repetitive baseline ECGs were recorded had ≥ 1 positive baseline ECG. In the present study, only 10 of 68 subjects (15%) in the S group always showed a type 1 Brugada ECG at a standard space with leads V₁ and V₂. Because a region reflecting the potentials of the right ventricular outflow tract includes higher precordial ECGs (second or third in leads V₁ and V₂), we hypothesized that recordings at a higher space in leads V₁ and V₂ would detect a type 1 coved-type Brugada ECG more frequently in patients with Brugada syndrome and transient ST-segment elevation. Shimizu et al¹² used body surface potential mapping and examined the body surface distribution of maximum (coved type) ST-segment elevation in patients with Brugada syndrome in whom spontaneous coved type ST-segment elevation was documented ≥ 1 time in the standard leads V₁ and V₂. They reported that the maximum ST-segment elevation was distributed at row 5 of the body surface potential mapping, on which leads V₁ and V₂ on standard ECG were located, in 18 of 25 patients (72%) with Brugada syndrome and at row 6, which was on the level of parasternal second intercostal space, in the remaining 7 patients (28%) with Brugada syndrome. In the latter patients, typical coved type ST-segment elevation was recognized only at a higher (third or second) space in leads V₁ and V₂ on the standard 12-lead ECG.

In the present study, the remaining 58 of 68 subjects (85%) in the S group did not always show a type 1

Brugada ECG on standard leads V₁ and V₂; however, 30 of 58 subjects (52%) always showed a type 1 Brugada ECG on the higher leads V₁ and V₂, suggesting that a higher electrocardiographic recording has higher sensitivity for detecting a type 1 Brugada ECG, as in previous studies.¹²⁻¹⁴ Moreover, higher recordings in leads V₁ and V₂ showed similar prognostic value as standard recordings in these leads. Because recordings of leads V₁ and V₂ at a higher (third or second) intercostal space are easy and noninvasive procedures, we recommend the higher recordings in leads V₁ and V₂ as an alternative to drug challenge testing with sodium channel blockers. Only when the result of this procedure is negative should a drug challenge test be considered as a next diagnostic test.

1. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. *J Am Coll Cardiol* 1992;20:1391-1396.
2. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. *Circulation* 2000; 101:510-515.
3. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, Corrado D, Hauer RN, Kass RS, Nademanee K, et al. for the Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology. Proposed diagnostic criteria for the Brugada syndrome: consensus report. *Circulation* 2002;106: 2514-2519.
4. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, Lemarec H, Nademanee K, Perez Riera AR, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005;111:659-670.
5. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, Lemarec H, Nademanee K, Perez Riera AR, et al. Brugada syndrome: report of the second consensus conference. *Heart Rhythm* 2005;2:429-440.
6. Kasanuki H, Ohnishi S, Ohtuka M, Matsuda N, Nirei T, Isogai R, Shoda M, Toyoshima Y, Hosoda S. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. *Circulation* 1997;95:2277-2285.
7. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, Tunsanga K, Kuasirikul S, Malasit P, Tansupasawadikul S, Tatsanavivat P. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. *Circulation* 1997;96:2595-2600.
8. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. *J Cardiovasc Electrophysiol* 1998;9:508-512.
9. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, Bloise R, Giustetto C, De Nardis R, Grillo M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation* 2002;105:1342-1347.
10. Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, Wichter T, Boisseau P, Heinecke A, Breithardt G, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. *Circulation* 2005;111:257-263.
11. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003;108:3092-3096.
12. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, Suyama K, Kurita T, Aihara N, Kamakura S. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential map-

- ping and its application to twelve-lead electrocardiograms. *J Cardiovasc Electrophysiol* 2000;11:396–404.
13. Sangwatanaroj S, Prechawat S, Sunsaneewitayakul B, Sitthisook S, Tosukhowong P, Tungsanga K. New electrocardiographic leads and the procainamide test for the detection of the Brugada sign in sudden unexplained death syndrome survivors and their relatives. *Eur Heart J* 2001;22:2290–2296.
 14. Nakazawa K, Sakurai T, Takagi A, Kishi R, Osada K, Miyazu O, Watanabe Y, Miyake F. Clinical significance of electrocardiography recordings from a higher intercostal space for detection of the Brugada sign. *Circ J* 2004;68:1018–1022.
 15. Gehi A, Duong T, Metz L, Gomes A, Mehta D. Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis. *J Cardiovasc Electrophysiol* 2006;17:577–583.

Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation

Takeshi Ohgo, MD, Hideo Okamura, MD, Takashi Noda, MD, PhD, Kazuhiro Satomi, MD, PhD, Kazuhiro Suyama, MD, PhD, Takashi Kurita, MD, PhD, Naohiko Aihara, MD, Shiro Kamakura, MD, PhD, Tohru Ohe, MD, PhD*, Wataru Shimizu, MD, PhD

From the Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, Osaka, Japan, and *Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan.

BACKGROUND Some patients with Brugada syndrome experience an electrical storm of ventricular fibrillation (VF).

OBJECTIVE The purpose of this study was to investigate the clinical, laboratory, electrocardiographic, and electrophysiologic characteristics, acute and subsequent chronic treatment, and follow-up data of patients with Brugada syndrome associated with electrical storm of VF.

METHODS Sixty-seven patients with Brugada syndrome (65 men and 2 women, age 46 ± 14 years) were divided into three groups: 7 patients with a history of electrical storm of VF (group I), 39 symptomatic patients with documented VF and/or syncope (group II), and 21 asymptomatic patients (group III). Electrical storm was defined as three or more episodes of VF per day recorded by the memory of an implantable cardioverter-defibrillator.

RESULTS No significant differences were observed among the three groups with regard to clinical (age at diagnosis, familial history of sudden cardiac death), laboratory (SCN5A mutation and serum potassium level), electrocardiographic and electrophysi-

ologic characteristics, and follow-up duration after diagnosis. However, arrhythmic events during follow-up after diagnosis and number of arrhythmic events per patient were significantly higher in group I compared with groups II and III. Isoproterenol infusion ($0.003 \pm 0.003 \mu\text{g}/\text{kg}/\text{min}$ for 24 ± 13 days) completely suppressed electrical storm of VF in all five patients treated and was successfully replaced with oral medications, including denopamine, quinidine, isoproterenol, cilostazol, and bepridil alone or in combination.

CONCLUSION No specifically clinical, laboratory, electrocardiographic, and electrophysiologic characteristics were recognized in patients with Brugada syndrome associated with electrical storm of VF. Isoproterenol infusion was effective as an acute treatment in suppressing electrical storm of VF and was successfully replaced with chronic oral medications.

KEYWORDS Brugada syndrome; Ventricular fibrillation; Electrical storm; Sudden cardiac death; Isoproterenol; Quinidine (Heart Rhythm 2007;4:695-700) © 2007 Heart Rhythm Society. All rights reserved.

Introduction

In 1992, Brugada and Brugada¹ described eight patients with a history of aborted sudden cardiac death (SCD) due to ventricular fibrillation (VF) and a distinct ECG pattern consisting of right bundle branch block and ST-segment elevation in the right precordial leads (V_1 - V_3) in the absence of any structural heart diseases.¹⁻⁷ At present, there is no specific pharmacologic treatment to prevent sudden death in patients with Brugada syndrome. Some patients with Bru-

gada syndrome experience an electrical storm of VF. Isoproterenol, a β -adrenergic agonist, is reported to decrease ST elevation and suppress repetitive episodes of VF in patients with Brugada syndrome probably because of its effect to augment L-type calcium current ($I_{\text{Ca-L}}$).⁸⁻¹² However, clinical characteristics and subsequent chronic management following acute therapy with isoproterenol infusion in patients with Brugada syndrome associated with electrical storm of VF is still unclear. In the present study, we investigated the clinical, electrocardiographic, and electrophysiologic characteristics and acute and subsequent chronic treatment in patients with Brugada syndrome associated with electrical storm of VF.

Methods

Study population

The study population consisted of 67 consecutive patients (65 men and 2 women, age 19-67 years, mean 46 ± 14 years) with Brugada syndrome who were admitted to the

Dr. W Shimizu was supported by the Uehara Memorial Foundation, the Hoansha Research Foundation, Japan Research Foundation for Clinical Pharmacology, Ministry of Education, Culture, Sports, Science and Technology Leading Project for Biosimulation, and Health Sciences Research Grants (H18-Research on Human Genome-002) from the Ministry of Health, Labour and Welfare, Japan. Address reprint requests and correspondence: Dr. Wataru Shimizu, Division of Cardiology, Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishiro-dai, Suita, Osaka, 565-8565 Japan. E-mail address: wshimizu@hsp.ncvc.go.jp. (Received December 14, 2006; accepted February 10, 2007.)




Figure 1 Effects of isoproterenol (ISP) infusion on ST-segment elevation and ventricular fibrillation (VF) in a patient with electrical storm of VF. Isoproterenol (0.002 $\mu\text{g}/\text{kg}/\text{min}$) decreased J-point amplitude and changed coved-type to saddleback-type ST-segment elevation in lead V_2 . Increasing dose of isoproterenol (0.004 $\mu\text{g}/\text{kg}/\text{min}$) normalized ST-segment elevation in lead V_2 and completely suppressed repetitive episodes of VF.

National Cardiovascular Center, Osaka, Japan, between 1994 and 2004. Brugada syndrome was diagnosed when type I coved-type ST-segment elevation (≥ 0.2 mV at J point) was observed in more than one of the right precordial leads (V_1 – V_3) in the presence or absence of a sodium channel blocker and in conjunction with one of the following: documented VF, polymorphic ventricular tachycardia (VT), family history of SCD at age younger than 45 years, coved-type electrocardiogram (ECG) in family members, inducibility of VF with programmed electrical stimulation, syncope, or nocturnal agonal respiration.¹³ Physical examination showed no abnormal findings, and no evidence of structural heart diseases was demonstrated by echocardiogram in any patients. Informed consent was obtained from all patients. The 67 patients with Brugada syndrome were divided into three groups; 7 patients (6 men) with a history of electrical storm of VF (group I), 39 symptomatic patients (38 men) with documented VF and/or syncope (group II), and 21 asymptomatic patients (21 men, group III).

The 21 patients in group III were diagnosed as having Brugada syndrome according to the following combination of diagnostic criteria in addition to the type I Brugada ECG: 11 patients with VF induction during electrophysiologic study, 4 patients with a family history of SCD, 2 patients with documented nonsustained polymorphic VT, 2 patients with nocturnal agonal respiration, and 2 patients with augmentation of ST elevation at early recovery phase after exercise. Electrical storm was defined as three or more episodes of VF per day recorded by

the memory of an implantable cardioverter-defibrillator (ICD) for at least 1 day. We retrospectively compared clinical, laboratory, electrocardiographic and electrophysiologic characteristics and follow-up data among the three groups. In the present study, patients were entered into the study upon diagnosis of Brugada syndrome. Study procedures, including 12-lead ECG, signal-averaged ECG, and electrophysiologic study, were performed during first symptomatic in-hospital admission (groups I and II) or in-hospital admission for evaluation of Brugada ECG (group III).

Twelve-lead ECG

Twelve-lead ECG data were recorded at a paper speed of 25 mm/s during sinus rhythm in the supine resting state.

Signal-averaged ECG

The late potential was analyzed using a signal-averaged ECG system (Arrhythmia Research Technology 1200EPX, Milwaukee, WI, USA). Three parameters were assessed using a computer algorithm: (1) total filtered QRS duration, (2) root mean square voltage of the terminal 40 ms of the filtered QRS complexes (V_{40}), and (3) duration of low-amplitude signals <40 μV of the filtered QRS complex (T_{40}). A late potential was considered present when the two criteria (V_{40} 38 ms) were fulfilled.

Electrophysiologic study

Electrophysiologic study was conducted without any antiarrhythmic drugs after informed consent was obtained. Pro-

Table 1 Clinical, laboratory, electrocardiographic, and electrophysiologic characteristics and follow-up

	Group I (n = 7)	Group II (n = 39)	Group III (n = 21)	P value
Clinical characteristics				
Age at diagnosis (years)	49.5 ± 15.9	45.5 ± 12.5	47.5 ± 11.4	NS
Previous VF or aborted cardiac arrest before diagnosis (%)	4/7 (57%)	24/39 (62%)	0/21 (0%)	<.05
Previous syncope alone before diagnosis (%)	3/7 (43%)	15/39 (38%)	0/21 (0%)	<.05
Family history of sudden cardiac death (%)	1/7 (14%)	3/39 (8%)	4/21 (19%)	NS
ICD placement (%)	7/7 (100%)	32/39 (82%)	12/21 (57%)	<.05
Duration after ICD placement (years)	8.2 ± 7.4	8.2 ± 2.3	5.3 ± 0.9	NS
Laboratory characteristics				
SCN5A mutation (%)	1/7 (14%)	3/39 (8%)	2/21 (10%)	NS
Serum potassium (mEq/L)	4.0 ± 0.4	4.2 ± 0.4	4.2 ± 0.4	NS
Electrocardiographic characteristics				
Spontaneous coved-type ST elevation (%)	4/7 (57%)	12/39 (31%)	10/21 (48%)	NS
J-point amplitude (mV)	0.35 ± 0.1	0.29 ± 0.2	0.37 ± 0.2	NS
QRS duration (ms)	103 ± 15	106 ± 17	103 ± 20	NS
PQ interval (ms)	159 ± 45	176 ± 37	167 ± 18	NS
Late potential (%)	4/6 (67%)	22/36 (62%)	9/19 (47%)	NS
Augmentation of ST elevation at early recovery phase after exercise (%)	5/6 (83%)	15/31 (48%)	8/17 (47%)	NS
Electrophysiologic characteristics				
Induction of VF (%)	4/7 (57%)	21/30 (70%)	11/15 (65%)	NS
Mode				
Triple	2	9	7	
Double	2	10	4	
Single	0	0	0	
HV interval (ms)	45 ± 10	44 ± 13	46 ± 12	NS
Follow-up				
Follow-up duration after diagnosis (years)	9.5 ± 4.8	8.7 ± 4.5	5.4 ± 1.2	NS
Arrhythmic events during follow-up (%)	7/7 (100%)	11/39 (28%)	2/21 (9%)	<.05
No. of arrhythmic events per patient	14.7	1.1	0.1	<.01
Electrical storm during follow-up (%)	7/7 (100%)	0/39 (0%)	0/7 (0%)	<.01
Duration between diagnosis and first electrical storm (years)	4.6 ± 4.7	NA	NA	
Follow-up duration after electrical storm (years)	5.0 ± 1.5	NA	NA	
Arrhythmic events after electrical storm (%)	5/7 (71%)	NA	NA	

ICD = implantable cardioverter-defibrillator; VF = ventricular fibrillation.

grammed electrical stimulation was performed from the right ventricular apex and right ventricular outflow tract with up to triple extrastimuli. The last extrastimulus was given up to 180 ms in older cases and up to 200 ms in recent cases. Induction of VF requiring direct cardioversion and/or polymorphic VT lasting >30 seconds was considered positive.

Acute treatment

If a patient had at least one episode of VF due to electrical storm of VF after admission, isoproterenol infusion was started until heart rate increased by 20% (Figure 1). If VF did not occur after admission, isoproterenol infusion was not used as an acute treatment, but oral medication (denopamine, an $\alpha+\beta$ -adrenergic agonist, or quinidine) was prescribed.

Chronic treatment

After repetitive episodes of VF were completely suppressed by isoproterenol infusion for more than 3 days, isoproterenol infusion was replaced with oral medications. Oral denopamine was prescribed initially. If VF recurred, other oral medications also were prescribed (quinidine, isoproterenol, clostazol, bepridil).

Follow-up

All patients were followed up at the outpatient clinic of the National Cardiovascular Center.

Statistical analysis

Quantitative values are expressed as mean ± SD. Statistical significance of differences was analyzed by Chi-square test or one-way analysis of variance among the three groups (group I vs group II vs group III). $P < .05$ was considered significant.

Results

Clinical, laboratory, electrocardiographic, and electrophysiologic characteristics of the three groups

The average number of VF episodes at electrical storm was 9.1 ± 6.8 (3–20) in the 7 group I patients. No specific triggers (e.g., fever, stress, drugs or concomitant illness) for the electrical storm have been noted.

Comparison of the clinical, laboratory, electrocardiographic, and electrophysiologic characteristics among the three groups is given in Table 1. There were no significant differences with regard to age at diagnosis, familial history